论文部分内容阅读
目的:观察替米沙坦对老年(年龄≥60岁)不稳定型心绞痛(UAP)患者外周血内皮祖细胞(EPCs)数量及高敏C反应蛋白(hs-CRP)的影响。方法:入选接受冠状动脉支架置入治疗(PCI)的老年UAP患者52例,随机分为替米沙坦组(PCI后加服替米沙坦80mg/d)和对照组(PCI后即刻加服安慰剂),PCI后即刻及4周后检测2组患者EPCs数量及hs-CRP水平的变化情况。结果:替米沙坦组与对照组PCI后即刻EPCs的数量基本相近;PCI 4周后2组EPCs数量均有所增加,但对照组与PCI后即刻比较差异无统计学意义。2组患者在PCI 4周后hs-CRP的水平均有明显的降低,但替米沙坦组降低的程度更为明显。结论:替米沙坦能够增加老年UAP患者EPCs的数量,显著降低其hs-CRP的水平,由此提示替米沙坦能够促进UAP患者EPCs的动员,有助于抑制机体的炎症反应,有助于改善老年UAP患者的预后。
Objective: To observe the effect of telmisartan on the number of peripheral blood EPCs and hs-CRP in patients with unstable angina (UAP) aged more than 60 years. Methods: Fifty-two elderly UAP patients undergoing coronary stenting (PCI) were randomly divided into telmisartan group (80 mg / d plus telmisartan after PCI) and control group (immediately after PCI plus Placebo). The number of EPCs and hs-CRP levels in two groups were detected immediately after PCI and after 4 weeks. Results: The number of EPCs immediately after PCI in telmisartan group and control group were almost the same. The number of EPCs in both groups increased after 4 weeks PCI, but there was no significant difference between control group and PCI immediately after PCI. The levels of hs-CRP in the two groups were significantly decreased after 4 weeks of PCI, but the extent of decrease was more obvious in the telmisartan group. Conclusion: Telmisartan can increase the number of EPCs in elderly patients with UAP, and significantly reduce the level of hs-CRP, suggesting that telmisartan can promote the mobilization of EPCs in UAP patients and help to suppress the body’s inflammatory response, which is helpful To improve the prognosis of elderly patients with UAP.